A Biomarker Exploratory Study of Efficacy and Prognosis of Dual Blockade of PD1/PDL1 and CTLA4 in Combination of Anti-angiogenic Treatment in MSS Metastatic Colorectal Cancers and MSI Solid Tumors Refractory to PD1/PDL1 Antibody Monotherapy
Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY
This study is a single-center prospective exploratory research, aiming to identify clinical characteristics and biomarkers associated with the therapeutic effects of dual PD1/PDL1 and CTLA4 blockade plus anti-angiogenic therapy and investigate MR image characteristics during treatment in patients with MSS metastatic colorectal cancer and MSI solid tumors resistant to PD-1/PD-L1 antibody monotherapy.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Pathologically confirmed MSS metastatic colorectal cancers or MSI solid tumors refractory to PD1/PDL1 antibody monotherapy
• Receiving dual blockade of PD1/PDL1 and CTLA4 in combination of anti-angiogenic treatment with or without other therapies
Locations
Other Locations
China
Jian Li
RECRUITING
Beijing
Contact Information
Primary
Zhenghang Wang
zhenghang_wang@bjmu.edu.cn
18813186790
Backup
Ting Xu
Time Frame
Start Date: 2024-01-10
Estimated Completion Date: 2028-09-30
Participants
Target number of participants: 50
Treatments
Exploratory group
Patients treated with dual blockade of PD1/PDL1 and CTLA4 in combination of anti-angiogenic treatment
Related Therapeutic Areas
Sponsors
Leads: Peking University Cancer Hospital & Institute